Literature DB >> 12501168

Enhancement of integrins by interleukin-1alpha, and their relationship with metastatic and invasive behavior of human pancreatic ductal adenocarcinoma cells.

Hirozumi Sawai1, Hiromitsu Takeyama, Minoru Yamamoto, Akiyoshi Furuta, Hitoshi Funahashi, Yuji Okada, Mikinori Sato, Moritsugu Tanaka, Tadao Manabe.   

Abstract

BACKGROUND AND OBJECTIVES: Adhesion and invasion of tumor cells to extracellular matrix (ECM) proteins play an important role in tumor metastasis formation. We investigated the enhancement of adhesive and invasive behavior to ECM proteins of human pancreatic cancer cells by interleukin-1alpha (IL-1alpha) to examine the mechanism of adhesion and invasion of metastatic human pancreatic cancer cells to ECM proteins.
METHODS: The enhancement of integrin subunits by IL-1alpha was examined by cellular enzyme-linked immunosorbent assay (CELISA) in two metastatic human pancreatic cancer cell lines (BxPC-3 and SW1990) and two nonmetastatic pancreatic cancer cell lines (PaCa-2 and PANC-1). In addition, assays of cancer cell adhesion and invasion to ECM proteins were performed to investigate whether increased integrin expression affected the invasive interaction between cancer cells and the putative integrin ECM ligands.
RESULTS: Expression of the alpha6 subunit by metastatic cancer cells was enhanced by IL-1alpha. Metastatic cancer cells also exhibited preferential adherence and invasion to laminin compared with nonmetastatic cancer cells, and this was enhanced by IL-1alpha.
CONCLUSIONS: The enhancement of alpha6beta1-integrin by Il-1alpha acting through IL-1RI, as well as the expression of alpha6beta1-integrin, plays an important role in metastasis formation in pancreatic cancer Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12501168     DOI: 10.1002/jso.10187

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

1.  Combined gemcitabine and alpha-interferon therapy for pancreatic cancer: report of a case.

Authors:  Hirozumi Sawai; Yuji Okada; Moritsugu Tanaka; Hitoshi Funahashi; Minoru Yamamoto; Hiromitsu Takeyama; Tadao Manabe
Journal:  Dig Dis Sci       Date:  2006-07       Impact factor: 3.199

2.  Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Authors:  Jason B Douglas; Debra T Silverman; Michael N Pollak; Yuzhen Tao; Amr S Soliman; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-10       Impact factor: 4.254

3.  Butyrate inhibits pancreatic cancer invasion.

Authors:  Buckminster Farrow; Piotr Rychahou; Kathleen L O'Connor; B Mark Evers
Journal:  J Gastrointest Surg       Date:  2003-11       Impact factor: 3.452

4.  The influence of reactive oxygen species on the adhesion of pancreatic carcinoma cells to the peritoneum.

Authors:  Sander ten Raa; Helma M U van Grevenstein; Miranda ten Kate; Kristin M Mangundap; Leo J Hofland; Hans Jeekel; Wim Sluiter; Casper H J van Eijck
Journal:  Cell Adh Migr       Date:  2007-04-11       Impact factor: 3.405

5.  Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB.

Authors:  Davide Melisi; Jiangong Niu; Zhe Chang; Qianghua Xia; Bailu Peng; Satoshi Ishiyama; Douglas B Evans; Paul J Chiao
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

6.  Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.

Authors:  Carlos A Orozco; Neus Martinez-Bosch; Pedro E Guerrero; Judith Vinaixa; Tomás Dalotto-Moreno; Mar Iglesias; Mireia Moreno; Magdolna Djurec; Françoise Poirier; Hans-Joachim Gabius; Martin E Fernandez-Zapico; Rosa F Hwang; Carmen Guerra; Gabriel A Rabinovich; Pilar Navarro
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-03       Impact factor: 11.205

7.  Whole Transcriptomic Analysis of Apigenin on TNFα Immuno-activated MDA-MB-231 Breast Cancer Cells.

Authors:  David Bauer; Elizabeth Mazzio; Karam F A Soliman
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

8.  Molecular characteristics of pancreatic ductal adenocarcinoma.

Authors:  Niki A Ottenhof; Roeland F de Wilde; Anirban Maitra; Ralph H Hruban; G Johan A Offerhaus
Journal:  Patholog Res Int       Date:  2011-03-27

9.  Interleukin-1 receptor antagonist inhibits angiogenesis in gastric cancer.

Authors:  Zhenqiang Gong; Jiachi Ma; He Su; Tiankang Guo; Hui Cai; Quan Chen; Xiaodan Zhao; Jianbo Qi; Jianbo Du
Journal:  Int J Clin Oncol       Date:  2018-01-17       Impact factor: 3.402

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.